Zealand Pharma AS (ZLDPF)
135.65
+2.24
(+1.68%)
USD |
OTCM |
Sep 20, 16:00
Zealand Pharma Revenue (Quarterly): 4.927M for June 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 4.927M |
| March 31, 2024 | 2.198M |
| December 31, 2023 | 3.353M |
| September 30, 2023 | 43.16M |
| June 30, 2023 | 1.521M |
| March 31, 2023 | 1.965M |
| December 31, 2022 | 3.289M |
| September 30, 2022 | 5.918M |
| June 30, 2022 | 3.635M |
| March 31, 2022 | 1.653M |
| December 31, 2021 | 2.066M |
| September 30, 2021 | 8.591M |
| June 30, 2021 | 5.923M |
| March 31, 2021 | 0.9247M |
| December 31, 2020 | -15.69M |
| September 30, 2020 | 8.880M |
| June 30, 2020 | 32.64M |
| March 31, 2020 | 1.833M |
| December 31, 2019 | 1.704M |
| September 30, 2019 | 1.478M |
| June 30, 2019 | 2.997M |
| March 31, 2019 | |
| December 31, 2018 | 2.006M |
| September 30, 2018 | |
| June 30, 2018 | 2.425M |
| Date | Value |
|---|---|
| March 31, 2018 | 1.604M |
| December 31, 2017 | 1.665M |
| September 30, 2017 | 6.177M |
| June 30, 2017 | 1.475M |
| March 31, 2017 | 11.12M |
| December 31, 2016 | 25.61M |
| September 30, 2016 | 5.936M |
| June 30, 2016 | 1.206M |
| March 31, 2016 | 0.9965M |
| December 31, 2015 | 24.51M |
| September 30, 2015 | 1.077M |
| June 30, 2015 | 1.081M |
| March 31, 2015 | 0.9601M |
| December 31, 2014 | 1.058M |
| September 30, 2014 | 10.35M |
| June 30, 2014 | 0.7891M |
| March 31, 2014 | 15.60M |
| December 31, 2013 | 0.5796M |
| September 30, 2013 | 0.4119M |
| June 30, 2013 | 0.1892M |
| March 31, 2013 | |
| December 31, 2012 | |
| September 30, 2012 | 6.273M |
| June 30, 2012 | 11.38M |
| March 31, 2012 | 21.21M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
-15.69M
Minimum
Dec 2020
43.16M
Maximum
Sep 2023
5.998M
Average
2.743M
Median
Revenue (Quarterly) Benchmarks
| Novo Nordisk AS | 9.824B |
| Eli Lilly and Co | 11.30B |
| Altimmune Inc | 0.005M |
| Genmab AS | 779.75M |
| Viking Therapeutics Inc | -- |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -42.26M |
| Total Expenses (Quarterly) | 43.56M |
| EPS Diluted (Quarterly) | -0.6741 |
| Enterprise Value | 8.380B |
| Gross Profit Margin (Quarterly) | 72.20% |
| Profit Margin (Quarterly) | -857.7% |
| Earnings Yield | -1.25% |
| Normalized Earnings Yield | -1.009 |